Sera Prognostics (SERA) Set to Announce Quarterly Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA - Get Free Report) will post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Sera Prognostics to post earnings of ($0.22) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.08 million. During the same period last year, the business posted ($0.34) EPS. On average, analysts expect Sera Prognostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sera Prognostics Stock Performance

Shares of NASDAQ:SERA traded up $1.06 during trading hours on Wednesday, hitting $8.14. 133,766 shares of the company's stock traded hands, compared to its average volume of 178,547. Sera Prognostics has a 52 week low of $1.65 and a 52 week high of $12.35. The company's fifty day simple moving average is $7.33 and its two-hundred day simple moving average is $7.81. The company has a market cap of $271.62 million, a price-to-earnings ratio of -8.31 and a beta of 1.03.

Insider Activity

In other Sera Prognostics news, insider John J. Boniface sold 5,022 shares of the firm's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total value of $37,263.24. Following the completion of the transaction, the insider now directly owns 129,847 shares in the company, valued at $963,464.74. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other Sera Prognostics news, insider John J. Boniface sold 5,022 shares of the firm's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total value of $37,263.24. Following the completion of the transaction, the insider now directly owns 129,847 shares in the company, valued at $963,464.74. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Austin Aerts sold 5,056 shares of the firm's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $7.57, for a total transaction of $38,273.92. Following the completion of the transaction, the chief financial officer now owns 298,665 shares of the company's stock, valued at approximately $2,260,894.05. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,543 shares of company stock worth $409,179. Corporate insiders own 15.80% of the company's stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.